Clinical trial NCT03473340: Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Official title: A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Disorder Related to Lung Transplantation
Chronic Lung Allograft Dysfunction
Keywords: CLAD
Chronic Rejection
Lung Transplant
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: Genentech, Inc.
First posted: 2018-03-22
Enrollment: 24
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Greater than 50% of lung transplant recipients show signs of chronic lung allograft dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are lacking. Anti-fibrotic therapies may offer an avenue to prevent progression of CLAD and prolong allograft survival. This study investigates if Pirfenidone therapy will stabilize lung function decline and slow progression of Functional small airways disease (fSAD) in lung transplant recipients with CLAD.

Detailed description: The study aimed to enroll lung transplant recipients with an established diagnosis of CLAD. The patients were randomized to receive an anti-fibrotic drug Pirfenidone or Placebo pills for 6 month period. High-resolution CT scan of the chest was utilized to measure the primary endpoint of change in functional small airway disease (fSAD). Pulmonary function testing and spirometry were utilized to measure the secondary endpoint of change in FEV1 and FVC.

Eligibility criteria: Inclusion Criteria:

* Lung transplant recipients 18 years of age or older
* Greater than 6 months after single or bilateral lung transplantation
* Baseline FEV1 and FVC values (mean of two highest value measured 3 weeks apart) \> 50% predicted (to assure viable graft)
* Diagnosis of CLAD (two consecutive spirometric values of FEV1 alone or both FEV1 and FVC \< 80% of baseline)

Exclusion Criteria

* Acute Rejection (AR) diagnosis by biopsy in the 28 days prior to enrollment
* Treatment with pulse steroids, Anti-thymocyte Globulin (ATG), extracorporeal photopheresis (ECP), plasmapheresis, or Immunoglobulin therapy aimed at CLAD within the 28 days prior to enrollment
* If the subject is receiving chronic Azithromycin therapy, the dose must be stable for the 28 days prior to enrollment
* Presence of active pulmonary infection at the time of enrollment as determined by an investigator in consultation with the treating pulmonologist
* Diagnosis of bronchial stenosis either a) requiring stenting, or b) thought to be responsible for the spirometric decline by principal investigator
* Abnormal liver function tests (aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2 x upper limit of normal (ULN), Alkaline phosphatase \> 2.5 x ULN, total bilirubin \> ULN) or known cirrhosis (\>2 times upper limit of normal of AST/ALT/AP)
* Total white blood cell (WBC) \< 3.0 K/uL
* Moderate to Severe Renal insufficiency (CrCl \<15 mL/min calculated by the Cockcroft-Gault equation)
* Use of any medication known to cause significant interactions with pirfenidone (strong CYP1A2 inhibitors such as Fluvoxamine or Enoxacin or inducers)
* Pregnancy or lactation. Women of child-bearing potential will have a pregnancy test at enrollment and must agree to maintain highly effective contraception with two methods of birth control from the date of consent through the end of the study.
* Tobacco use within 6 months
* History of alcohol abuse in the past 1 year as determined by the treating pulmonologist
* Any condition other than CLAD that will likely result in death in the next 1 year
* Any condition in the judgement of the principal investigator that would preclude participation in this study
* EKG with QTc interval \> 500 msec at screening
* Listed for repeat lung transplantation

Primary outcomes:
measure: Change in Percent of Functional Small Airways Disease (fSAD) as Measured by Parametric Response Mapping
timeFrame: Baseline, 24 weeks
Secondary outcomes:
measure: Change in Forced Expiratory Volume 1 Over 24 Weeks (FEV1)
timeFrame: Baseline, 24 weeks
measure: Change in Forced Vital Capacity (FVC) Over 24 Weeks
timeFrame: Baseline, 24 weeks
measure: Number of Adverse Events Related to Study Treatment
timeFrame: 28 weeks
measure: Number of Subjects With Treatment Intolerance
timeFrame: 24 weeks
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: The University of Michigan
state: Michigan
Study officials:
affiliation: University of Michigan
name: Vibha Lama, MD
role: PRINCIPAL_INVESTIGATOR
References: